Processa Pharmaceuticals filings document formal 8-K and amended 8-K disclosures for a clinical-stage biopharmaceutical issuer. The records cover material events involving licensing and term-sheet matters, Nasdaq listing compliance, executive-officer status changes and compensatory arrangements, and shareholder-vote reporting.
The company's filings also describe capital-structure and charter actions, including amendments to its certificate of incorporation, authorized-share changes, reverse stock split mechanics, common-stock rights and related governance approvals. These disclosures frame Processa's public-company status, equity structure and corporate governance alongside its development-stage pharmaceutical business.
Processa Pharmaceuticals, Inc. reported that Chief Administrative Officer Wendy Guy received a grant of 9,450 Restricted Stock Units on 2026-07-26, each representing one share of common stock. These RSUs vested on grant but will be delivered in shares at the earlier of termination, six months after grant, a change of control, or death.
After this award, Guy holds 11,669 RSUs directly, stock options for 6,000 shares at an exercise price of $4.9600 vesting over three years, 14,394 shares of common stock directly, and 333 shares indirectly through CorLyst, LLC.
Baluch Khoso reported acquisition or exercise transactions in this Form 4 filing.
Processa Pharmaceuticals, Inc. director Baluch Khoso received a grant of 33,500 Restricted Stock Units on 26 July 2026, each representing one share of common stock. The RSUs vested immediately but will be distributed only upon termination, six months after grant, a change of control, or death. Following this award, Khoso holds 38,749 RSUs, 12,000 stock options to buy common shares at $4.96, and 2,528 common shares directly, all reflecting a 1-for-25 reverse stock split completed in December 2025.
Processa Pharmaceuticals insider activity: Chief Administrative Officer Guy Wendy bought 2,436 shares of common stock in an open-market purchase at $1.93 per share. After this trade, she holds 14,394 shares directly and 333 shares indirectly through CorLyst, LLC.
Processa Pharmaceuticals, Inc. executive Patrick Lin, Chief Business-Strategy Officer, bought additional common stock in the company. On June 30, 2026, he made an open-market purchase of 2,106 shares at $1.93 per share.
After this transaction, Lin directly holds 13,113 common shares. The filing also lists an indirect holding of 1,740 shares registered under the Lin Family Trust dated February 4, 2024, giving investors a clearer view of both his direct and trust-related ownership.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng bought 3,057 shares of Common Stock in an open-market purchase at $1.93 per share on July 1, 2026. After this trade, he directly owns 15,492 shares, plus additional indirect holdings through related entities.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of 3,277 shares of Common Stock at $1.93 per share. After this transaction, he directly owns 16,689 shares. This filing reflects a relatively small insider buy by a senior executive.
Processa Pharmaceuticals, Inc. director and officer David Young bought additional common stock in an open-market transaction. On June 30, 2026, he purchased 2,531 shares at $1.93 per share, bringing his direct holdings to 21,729 shares of common stock.
He also reports indirect ownership of common stock through several entities as of that date: 1,009 shares held by CorLyst, LLC, 432 shares held by Family Entities, and 1,242 shares held by the Young-Plaisance Revocable Trust.
Processa Pharmaceuticals director Justin W. Yorke reported a routine equity compensation event. On June 26, 2026, he exercised a time-based service restricted stock award, converting 203 restricted shares into 203 shares of common stock at $0.00 per share.
After the transaction, Yorke holds 353 common shares directly, plus 496 common shares held indirectly through a directed trust IRA and 1,250 common shares held indirectly via Richland Fund, LLC. He also continues to hold 5,249 restricted stock units directly.
Processa Pharmaceuticals director Geraldine Pannu reported a routine equity compensation event. She exercised a derivative award relating to 203 shares of Common Stock on June 26, 2026, at a stated exercise price of $0.00 per share, tied to a time-based service award.
Following the transaction, her direct holdings of Common Stock increased to 2,391 shares. The related Restricted Stock position, which served as the derivative security, showed 5,249 units following the exercise. The filing characterizes this as an exercise or conversion of a derivative security, reflecting compensation rather than an open-market trade.
Processa Pharmaceuticals director Neal James R reported a compensation-related share vesting. On June 26, 2026, he exercised a time-based service award, converting 203 shares of restricted stock into 203 shares of common stock at a stated price of $0.00 per share.
After the transaction, he directly holds 1,021 shares of common stock and 5,249 shares of restricted stock. The filing shows an exercise of a derivative security rather than any open-market purchase or sale of Processa Pharmaceuticals stock.